Logo image of ALVR

ALLOVIR INC (ALVR) Stock Analyst Ratings

NASDAQ:ALVR - Nasdaq - US0198181036 - Common Stock

9.2  -0.18 (-1.92%)

Buy % Consensus

43

ChartMill assigns a Buy % Consensus number of 43% to ALVR. The Buy consensus is the weighted average rating of the current analysts ratings.

ALVR was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about ALVR.
In the previous month the buy percentage consensus was at a similar level.
ALVR was analyzed by 6 analysts. More opinions would make the average more meaningful.
ALVR Historical Analyst RatingsALVR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -52 -47 -42 -37 -32 -27 -22 -17 -12 -7 -2 2 4 6 8 10
ALVR Current Analyst RatingALVR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5
Up and Down Grades
Date Firm Action Rating
2023-12-26 B of A Securities Downgrade Buy -> Underperform
2023-12-22 Leerink Partners Downgrade Outperform -> Market Perform
2023-12-22 JP Morgan Downgrade Overweight -> Underweight
2023-12-22 Piper Sandler Downgrade Overweight -> Neutral
2023-08-18 B of A Securities Initiate Buy
2023-08-07 Morgan Stanley Reiterate Overweight -> Overweight
2023-04-26 SVB Securities Maintains Outperform
2023-01-27 Morgan Stanley Maintains Overweight
2023-01-23 SVB Leerink Maintains Outperform
2022-11-07 SVB Leerink Maintains Outperform
2022-09-09 Morgan Stanley Maintains Overweight
2022-07-28 SVB Leerink Maintains Outperform
2022-05-19 Piper Sandler Maintains Overweight
2022-02-10 SVB Leerink Maintains Outperform
2022-02-01 BMO Capital Initiate Outperform
2022-01-18 Morgan Stanley Maintains Overweight
2021-12-17 SVB Leerink Maintains Outperform
2021-11-08 SVB Leerink Maintains Outperform
2021-10-12 Morgan Stanley Maintains Overweight
2021-09-29 Morgan Stanley Maintains Overweight
2021-08-18 Morgan Stanley Maintains Overweight
2021-05-06 SVB Leerink Maintains Outperform
2021-04-19 Morgan Stanley Maintains Overweight